Random mutagenesis reveals residues of JAK2 critical in evading inhibition by a tyrosine kinase inhibitor

PLoS ONE

Volumn 7, Issue 8, 2012, Pages

  Marit, Michael R ^a,b   Chohan, Manprit ^a,b   Matthew, Natasha ^b   Huang, Kai ^b   Kuntz, Douglas A ^b   Rose, David R ^a,b,c   Barber, Dwayne L ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b PRINCESS MARGARET HOSPITAL   (Canada)

^c UNIVERSITY OF WATERLOO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

JANUS KINASE 1 INHIBITOR; JANUS KINASE 2; JANUS KINASE 2 INHIBITOR; JANUS KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE B; PROTEIN TYROSINE KINASE INHIBITOR; STAT5 PROTEIN; UNCLASSIFIED DRUG;

ALLELE; ANIMAL CELL; ARTICLE; CANCER RESISTANCE; CELL GROWTH; CELL ISOLATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ACTIVITY; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME MECHANISM; ENZYME PHOSPHORYLATION; ENZYME SUBSTRATE; GENE; GENE MUTATION; GENETIC SCREENING; HUMAN; HUMAN CELL; IN VITRO STUDY; JAK2 GENE; MUTAGENESIS; NONHUMAN; SATURATION MUTAGENESIS; SIGNAL TRANSDUCTION;

CELL LINE; CELLS, CULTURED; ELECTROPHORESIS, POLYACRYLAMIDE GEL; HUMANS; JANUS KINASE 2; MUTAGENESIS; PROTEIN KINASE INHIBITORS;

EID: 84865062499     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0043437     Document Type: Article

References (55)

1. Tefferi A, Vainchenker W, (2011) Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 29: 573-582.
2. Levine RL, Gilliland DG, (2008) Myeloproliferative disorders. Blood 112: 2190-2198.
3. Levine RL, Pardanani A, Tefferi A, Gilliland DG, (2007) Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. Nature reviews Cancer 7: 673-683.
4. Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, et al. (2005) Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer cell 7: 387-397.
5. Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, et al. (2005) A gain-of-function mutation of JAK2 in myeloproliferative disorders. The New England journal of medicine 352: 1779-1790.
6. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, et al. (2005) Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365: 1054-1061.
7. James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, et al. (2005) A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434: 1144-1148.
8. Ungureanu D, Wu J, Pekkala T, Niranjan Y, Young C, et al. (2011) The pseudokinase domain of JAK2 is a dual-specificity protein kinase that negatively regulates cytokine signaling. Nature structural & molecular biology 18: 971-976.
9. Lu X, Levine R, Tong W, Wernig G, Pikman Y, et al. (2005) Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation. Proceedings of the National Academy of Sciences of the United States of America 102: 18962-18967.
10. Rowley JD, (1973) Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 243: 290-293.
11. Konopka JB, Watanabe SM, Witte ON, (1984) An alteration of the human c-abl protein in K562 leukemia cells unmasks associated tyrosine kinase activity. Cell 37: 1035-1042.
12. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, et al. (1996) Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nature medicine 2: 561-566.
13. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, et al. (2001) Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. The New England journal of medicine 344: 1031-1037.
14. Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, et al. (2001) Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. The New England journal of medicine 344: 1038-1042.
15. Buchdunger E, Zimmermann J, Mett H, Meyer T, Muller M, et al. (1996) Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer research 56: 100-104.
16. Sawyers CL, Hochhaus A, Feldman E, Goldman JM, Miller CB, et al. (2002) Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 99: 3530-3539.
17. le Coutre P, Tassi E, Varella-Garcia M, Barni R, Mologni L, et al. (2000) Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification. Blood 95: 1758-1766.
18. Mahon FX, Deininger MW, Schultheis B, Chabrol J, Reiffers J, et al. (2000) Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood 96: 1070-1079.
19. Shah NP, Nicoll JM, Nagar B, Gorre ME, Paquette RL, et al. (2002) Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer cell 2: 117-125.
20. Branford S, Rudzki Z, Walsh S, Grigg A, Arthur C, et al. (2002) High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood 99: 3472-3475.
21. Azam M, Latek RR, Daley GQ, (2003) Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL. Cell 112: 831-843.
22. Bradeen HA, Eide CA, O'Hare T, Johnson KJ, Willis SG, et al. (2006) Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations. Blood 108: 2332-2338.
23. Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, et al. (2006) Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. The New England journal of medicine 354: 2531-2541.
24. Kantarjian HM, Giles FJ, Bhalla KN, Pinilla-Ibarz J, Larson RA, et al. (2011) Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results. Blood 117: 1141-1145.
25. O'Hare T, Walters DK, Stoffregen EP, Jia T, Manley PW, et al. (2005) In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer research 65: 4500-4505.
26. Shah NP, Tran C, Lee FY, Chen P, Norris D, et al. (2004) Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 305: 399-401.
27. Zhang J, Adrian FJ, Jahnke W, Cowan-Jacob SW, Li AG, et al. (2010) Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors. Nature 463: 501-506.
28. Weisberg E, Deng X, Choi HG, Barrett R, Adamia S, et al. (2010) Beneficial effects of combining a type II ATP competitive inhibitor with an allosteric competitive inhibitor of BCR-ABL for the treatment of imatinib-sensitive and imatinib-resistant CML. Leukemia: official journal of the Leukemia Society of America, Leukemia Research Fund, UK 24: 1375-1378.
29. Chan WW, Wise SC, Kaufman MD, Ahn YM, Ensinger CL, et al. (2011) Conformational control inhibition of the BCR-ABL1 tyrosine kinase, including the gatekeeper T315I mutant, by the switch-control inhibitor DCC-2036. Cancer cell 19: 556-568.
30. Jamieson CH, Barroga CF, Vainchenker WP, (2008) Miscreant myeloproliferative disorder stem cells. Leukemia: official journal of the Leukemia Society of America, Leukemia Research Fund, UK 22: 2011-2019.
31. Pardanani A, Tefferi A, (2011) Targeting myeloproliferative neoplasms with JAK inhibitors. Current opinion in hematology 18: 105-110.
32. Verstovsek S, Kantarjian H, Mesa RA, Pardanani AD, Cortes-Franco J, et al. (2010) Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. The New England journal of medicine 363: 1117-1127.
33. Santos FP, Kantarjian HM, Jain N, Manshouri T, Thomas DA, et al. (2010) Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis. Blood 115: 1131-1136.
34. Swift S, Lorens J, Achacoso P, Nolan GP (2001) Rapid production of retroviruses for efficient gene delivery to mammalian cells using 293T cell-based systems. Current protocols in immunology/edited by John E Coligan [et al] Chapter 10: Unit 10 17C.
35. Barber DL, DeMartino JC, Showers MO, D'Andrea AD, (1994) A dominant negative erythropoietin (EPO) receptor inhibits EPO-dependent growth and blocks F-gp55-dependent transformation. Molecular and cellular biology 14: 2257-2265.
36. Li Z, Xing S, Wang S, Ho WT, Zhao ZJ, (2007) Characterization of a highly effective protein substrate for analysis of JAK2(V617F) Activity. Experimental hematology 35: 1624-1632.
37. Hart S, Goh KC, Novotny-Diermayr V, Hu CY, Hentze H, et al. (2011) SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies. Leukemia: official journal of the Leukemia Society of America, Leukemia Research Fund, UK 25: 1751-1759.
38. Grandage VL, Everington T, Linch DC, Khwaja A, (2006) Go6976 is a potent inhibitor of the JAK 2 and FLT3 tyrosine kinases with significant activity in primary acute myeloid leukaemia cells. British journal of haematology 135: 303-316.
39. Haan S, Wuller S, Kaczor J, Rolvering C, Nocker T, et al. (2009) SOCS-mediated downregulation of mutant Jak2 (V617F, T875N and K539L) counteracts cytokine-independent signaling. Oncogene 28: 3069-3080.
40. Hofmann WK, Komor M, Wassmann B, Jones LC, Gschaidmeier H, et al. (2003) Presence of the BCR-ABL mutation Glu255Lys prior to STI571 (imatinib) treatment in patients with Ph+ acute lymphoblastic leukemia. Blood 102: 659-661.
41. Willis SG, Lange T, Demehri S, Otto S, Crossman L, et al. (2005) High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy. Blood 106: 2128-2137.
42. Lacronique V, Boureux A, Valle VD, Poirel H, Quang CT, et al. (1997) A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia. Science 278: 1309-1312.
43. Peeters P, Raynaud SD, Cools J, Wlodarska I, Grosgeorge J, et al. (1997) Fusion of TEL, the ETS-variant gene 6 (ETV6), to the receptor-associated kinase JAK2 as a result of t(9;12) in a lymphoid and t(9;15;12) in a myeloid leukemia. Blood 90: 2535-2540.
44. Pradhan A, Lambert QT, Griner LN, Reuther GW, (2010) Activation of JAK2-V617F by components of heterodimeric cytokine receptors. The Journal of biological chemistry 285: 16651-16663.
45. Schaub FX, Looser R, Li S, Hao-Shen H, Lehmann T, et al. (2010) Clonal analysis of TET2 and JAK2 mutations suggests that TET2 can be a late event in the progression of myeloproliferative neoplasms. Blood 115: 2003-2007.
46. Stein BL, Williams DM, O'Keefe C, Rogers O, Ingersoll RG, et al. (2011) Disruption of the ASXL1 gene is frequent in primary, post-essential thrombocytosis and post-polycythemia vera myelofibrosis, but not essential thrombocytosis or polycythemia vera: analysis of molecular genetics and clinical phenotypes. Haematologica.
47. Lucet IS, Fantino E, Styles M, Bamert R, Patel O, et al. (2006) The structural basis of Janus kinase 2 inhibition by a potent and specific pan-Janus kinase inhibitor. Blood 107: 176-183.
48. Hornakova T, Springuel L, Devreux J, Dusa A, Constantinescu SN, et al. (2011) Oncogenic JAK1 and JAK2-activating mutations resistant to ATP-competitive inhibitors. Haematologica 96: 845-853.
49. Deshpande A, Reddy MM, Schade GO, Ray A, Chowdary TK, et al. (2011) Kinase domain mutations confer resistance to novel inhibitors targeting JAK2V617F in myeloproliferative neoplasms. Leukemia: official journal of the Leukemia Society of America, Leukemia Research Fund, UK.
50. Weigert O, Lane AA, Bird L, Kopp N, Chapuy B, et al. (2012) Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition. The Journal of experimental medicine 209: 259-273.
51. Vijayakrishnan L, Venkataramanan R, Gulati P, (2011) Treating inflammation with the Janus kinase inhibitor CP-690,550. Trends in pharmacological sciences 32: 25-34.
52. Changelian PS, Flanagan ME, Ball DJ, Kent CR, Magnuson KS, et al. (2003) Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor. Science 302: 875-878.
53. Opar A, (2010) Kinase inhibitors attract attention as oral rheumatoid arthritis drugs. Nature reviews Drug discovery 9: 257-258.
54. Ju W, Zhang M, Jiang JK, Thomas CJ, Oh U, et al. (2011) CP-690,550, a therapeutic agent, inhibits cytokine-mediated Jak3 activation and proliferation of T cells from patients with ATL and HAM/TSP. Blood 117: 1938-1946.
55. Haan C, Kroy DC, Wuller S, Sommer U, Nocker T, et al. (2009) An unusual insertion in Jak2 is crucial for kinase activity and differentially affects cytokine responses. Journal of immunology 182: 2969-2977.